Impact of Aspergillus spp. isolation in the first 24 hours of admission in critically ill patients with severe influenza virus pneumonia.

Aspergillosis Aspergilosis Critically ill Enfermo crítico IAPA Immunosupression Influenza Inmunosupresión

Journal

Medicina intensiva
ISSN: 2173-5727
Titre abrégé: Med Intensiva (Engl Ed)
Pays: Spain
ID NLM: 101717568

Informations de publication

Date de publication:
08 2022
Historique:
received: 20 09 2021
accepted: 05 12 2021
entrez: 22 7 2022
pubmed: 23 7 2022
medline: 27 7 2022
Statut: ppublish

Résumé

To determine the incidence and impact of Aspergillus spp. isolation (AI) on ICU mortality in critically ill patients with severe influenza pneumonia during the first 24h of admission. Secondary analysis of an observational and prospective cohort study. ICUs voluntary participating in the Spanish severe Influenza pneumonia registry, between June 2009 and June 2019. Consecutive patients admitted to the ICU with diagnosis of severe influenza pneumonia, confirmed by real-time polymerase chain reaction. None. Incidence of AI in respiratory samples. Demographic variables, comorbidities, need for mechanical ventilation and the presence of shock according at admission. Acute Physiology and Chronic Health Evaluation II (APACHE II) scale calculated on ICU admission. 3702 patients were analyzed in this study. AI incidence was 1.13% (n=42). Hematological malignancies (OR 4.39, 95% CI 1.92-10.04); HIV (OR 3.83, 95% CI 1.08-13.63), and other immunosuppression situations (OR 4.87, 95% CI 1.99-11.87) were factors independently associated with the presence of Aspergillus spp. The automatic CHAID decision tree showed that hematologic disease with an incidence of 3.3% was the most closely AI related variable. Hematological disease (OR 2.62 95% CI 1.95-3.51), immunosuppression (OR 2.05 95% CI 1.46-2.88) and AI (OR 3.24, 95% CI 1.60-6.53) were variables independently associated with ICU mortality. Empirical antifungal treatment in our population may only be justified in immunocompromised patients. In moderate-high risk cases, active search for Aspergillus spp. should be implemented.

Identifiants

pubmed: 35868719
pii: S2173-5727(22)00156-4
doi: 10.1016/j.medine.2021.12.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

426-435

Informations de copyright

Copyright © 2021 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.

Auteurs

L Claverias (L)

Critical Care Department, Hospital Universitari Joan XXIII, Tarragona, Spain; Institut d'Investigació Sanitaria Pere Virgili, Reus, Spain. Electronic address: lauraclaverias@gmail.com.

X Daniel (X)

Critical Care Department, Hospital Universitari Joan XXIII, Tarragona, Spain.

I Martín-Loeches (I)

Multidisciplinary Intensive Care Research Organization (MICRO), Department of Intensive Care Medicine, St James's University Hospital, Dublin, Ireland.

P Vidal-Cortez (P)

Critical Care Department, Complejo Hospitalario Universitario Ourense, Spain.

F Gómez-Bertomeu (F)

Microbiology Department, Hospital Universitari Joan XXIII, Tarragona, Spain.

S Trefler (S)

Critical Care Department, Hospital Universitari Joan XXIII, Tarragona, Spain; Institut d'Investigació Sanitaria Pere Virgili, Reus, Spain.

R Zaragoza (R)

Critical Care Department, Hospital Dr Peset, Valencia, Spain.

M Borges-Sa (M)

Multidisciplinar Sepsis Unit, Critical Care Department, Hospital Son Llàtzer, Palma de Mallorca, Spain.

L F Reyes (LF)

Infectious Diseases Department, Universidad de La Sabana, Chía, Colombia; Critical Care Department, Clinica Universidad de La Sabana, Chía, Colombia.

G Quindós (G)

Department of Immunology, Microbiology and Parasitology, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Bilbao, Spain.

J Peman (J)

Institute of Sanitary Investigation La Fe, Hospital Universitari I Politècnic La Fe, Valencia, Spain.

M Bodí (M)

Critical Care Department URV/IISPV/CIBERES, Hospital Universitari Joan XXIII Tarragona, Spain.

E Díaz (E)

Critical Care Department, Hospital Parc Taulí, Sabadell, Spain.

C Sarvisé (C)

Microbiology Department, Hospital Universitari Joan XXIII, Tarragona, Spain.

E Pico (E)

Microbiology Department, Hospital Universitari Joan XXIII, Tarragona, Spain.

E Papiol (E)

Critical Care Department, Hospital Valle Hebrón, Barcelona, Spain.

J Solé-Violan (J)

Critical Care Department Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.

J Marín-Corral (J)

Critical Care Department, Hospital del Mar, Barcelona, Spain.

J J Guardiola (JJ)

Department of Pulmonary, Critical Care and Sleep Medicine, University of Louisville, USA.

A Rodríguez (A)

Critical Care Department URV/IISPV/CIBERES, Hospital Universitari Joan XXIII Tarragona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH